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Patient Reported Efficacy of Botulinum Toxin Type A in the Treatment of Chronic  
Migraine Headaches 
Patrick F. Whitney 
ABSTRACT 
Objective: To assess patient reported efficacy of Botulinum toxin type-A for the 
prophylaxis of migraine headaches in patients with frequent migraine headaches prior to 
initiation of treatment with Botulinum toxin type-A compared to post treatment.  
Questions addressed include is there a difference in frequency of migraine headaches 
following treatment with Botulinum toxin type-A, is there a difference in cost of 
conventional treatment versus Botulinum toxin type-A and is there a difference in quality 
of life. 
Research Plan:  Questions addressed patient status prior to the initiation of treatment as 
well as post treatment.  Patient quality of life change, duration and frequency headache 
improvement are the primary focus.  Other considerations included the cost difference 
between the previous use of other treatment and the periodic treatment with Botulinum 
toxin type-A.  
Methodology:  A Cross Sectional study utilizing a questionnaire consisting of a modified 
Migraine Disability Assessment (MIDAS) questionnaire will be given to patients who 
had received more than one series of injections.  Patients who reported chronic migraine 
headaches and were refractory to previous treatment methods were screened and placed 
 v
in programs utilizing intramuscular injection of Botulinum toxin type-A at standard 
points on the face, Temporalis muscle and paracervical muscles. 
Clinical Relevance:  This assessment is relevant to occupational issues due to the 
increasing number of patients applying for disability due to uncontrolled migraine 
headaches as well as lost productivity and reduction in functional capacity for activities 
of daily living.       
Impact and Significance:  Patient’s that are debilitated by recurrent chronic migraine 
headaches suffer loss of productive time at work and home.  Treatment with Botulinum 
toxin type-A may results in significant relief allowing fewer days lost at work and 
improved quality of life.  There may be significant cost saving if treatment results in 
discontinuation of other medications previously used for treatment of migraine 
headaches. 
Findings:  According to the patients’ responses to this survey, it appears that there was 
an overall improvement in the patients’ ability to do work, for those who were employed, 
as well as their ability to do activities of daily living post treatment with Botulinum toxin-
A.  Though there were occasionally conflicting data seen in individual cases regarding 
responses to some of the answers, there appeared to be an overall statistically significant 
reduction in the mean of responses to the questions.  The general implication is consistent 
with studies that indicate Botulinum toxin-A may be a useful adjunct in the prophylactic 
treatment of refractory migraine headaches. 
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Background 
Migraine headaches have become a significant source of lost work in the US.  Social 
Security disability claims arising from migraine headaches have become more 
increasingly more common in recent years.  It is estimated that 30 million Americans 
suffer occasionally or regularly with migraine headaches.  It is estimated that 113 million 
lost work days are due to migraines with $13 billion of lost productivity (1).  Migraine 
ranks in the top 20 of the world's most disabling medical illnesses. Estimates of the US 
population suffering from migraine headaches vary in range from 2 - 10% (1,2). The onset 
of a migraine headache is potentially disabling in itself, however many sufferers live 
knowing that at any time the onset of a headache could disrupt their ability to work, go to 
school, care for their families or generally interfere with activities of daily living. Less 
than 10% of those with migraine history are able to work or function normally during 
their migraine attacks (1).  About 12 million people experience these attacks on an almost 
daily basis placing them well outside of the average rate of once or twice a month for the 
typical migraine headache sufferer. These may be referred to as chronic daily headache 
(CDH) and are defined as a group of disorders characterized by very frequent headaches 
occurring 15 days a month and include those headaches associated with medication 
overuse (3).  In the US, women have a higher prevalence than men at an estimated 18% 
vs. 6%.  Over 30 million people in the United States cause American employers lose 
more than $13 billion each year as a result of 113 million lost work days due to migraine 
headaches.  In the 2005 European Journal of Neurology, it was estimated that migraine 
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headaches were the most costly neurological disorder in the European Community 
costing more than €27 billion per year (15). Annual employer cost of lost productivity due 
to migraines has been estimated at $3,309 per sufferer. Total medical costs associated 
with migraines in the United States amounted to one billion dollars in 1994 and when 
combined with the cost of lost productivity is estimated at thirteen to seventeen billion 
dollars per year.  In a recent aritcle published in the Journal of Occupational and 
Environmental Medicine, a study was published evaluating the impact on the workplace 
of chronic migraine headaches as compared to episodic migraine headaches (65).  
Estimates of lost productivity time were based on 2005 data derived from American 
Migriane Prevalence and Prevention (AMPP) study.  This was a large study surveying 
11,000 individuals with migraine headaches.  The survey was done on patients over 18 
years of age suffering from at least occasional self defined severe headaches.  Migraine 
case definition included established critreia of unilateral or pulsatile pain with nausea, 
vomiting, phonophobia, photophobia or unusual aura preceeding the headache.  The 
questionairre was initiated in 2004 with a second follow up survey in 2005.  The results 
of the study indicate that individuals with chronic migraine headaches were 19% less 
likely to be working as compared to those who experienced headaches at less than or 
equal to 3 headace days per month.  The average time lost per week for those with 
chronic migraine headaches was 4.6 hours as compared to only 1.1 hours per week for 
those with less frequent headaches.  Those in the chronic migraine group accounted for 
20.8% of lost productivity time and 35% of overall lost work time when factoring in 
medical leave and unemployment.  The study concluded that the impact of chronic 
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migraine headaches as well as episodic migraine headaches would be underestimated if 
employment status is not measured (65). 
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Migraine Mechanism 
Migraine attacks often include features that occur in sequence beginning with the 
prodrome stage. This stage is marked by a change in mood that begins hours or days 
before the headache. Symptoms of prodrome include depression, sleepiness, 
talkativeness, restlessness, or other alterations (6).   Next is the Aura phase characterized 
by visual abnormalities, including flashes, shimmering, and other hallucinations.  Finally 
the headache phase occurs. The headache itself is typically one sided but may also 
present as bilateral. It is usually gradual in onset with moderate to severe in pain 
intensity.  Throbbing and worse pain occurs with physical exertion. The headache can 
last anywhere from 2 hours to 2 days in children and 4 hours to 3 days in adults (6). The 
frequency of migraine attacks is difficult to predict. The headache stage is often 
accompanied by decreased appetite, nausea, vomiting, sensitivity to light and sound, 
blurred vision, tenderness of the scalp or neck, lightheadedness, sweating, and pallor (6).  
The cause of migraine headaches appears to be multifaceted consequently no single 
treatment protocol has been uniformly successful leaving migraine patients dissatisfied 
with treatment results.  Numerous theories as to the origin and mechanism of migraine 
headaches have been proposed over the years.  One of the first theories to explain 
migraines was the classic theory of vasoconstriction/vasodilatation. According to this 
theory, migraine headaches are caused by the constriction of blood vessels in the brain 
which is followed by vasodilatation (7). During the 1940s and 1950s, the vascular theory 
was proposed to explain the pathophysiology of migraine headache. Wolff et al believed 
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that intracranial vasoconstriction is responsible for the aura of migraine and that the 
subsequent rebound vasodilatation with activation of perivascular nociceptive nerves 
resulted in headache. This theory was based on the observations that extracranial vessels 
become distended and pulsatile during a migraine attack and stimulation of intracranial 
vessels in an awake person induces headache.  He also noted that vasoconstrictors such as 
ergotamine improve the headache, whereas vasodilators such as nitroglycerin provoke an 
attack. However, this theory has been challenged recently for several reasons.  Brain 
studies during migraine have shown that blood flow to the brain is in fact abnormal, 
which likely contributes to the symptoms.  The current view is that a complex series of 
neural and vascular events initiates migraine. This view is now called the neurovascular 
theory (11).  Key features of the neurovascular theory include the following.  At baseline, a 
migraineur who is not having any headache has a state of neuronal hyperexcitability in 
the cerebral cortex, especially in the occipital cortex (12). This finding has been 
demonstrated in studies of transcranial magnetic stimulation and with functional MRI. 
This observation explains the special susceptibility of the migrainous brain to headaches 
(13).  There is speculation that there is a parallel with the patient with epilepsy who 
similarly has interictal neuronal irritability.   The theory of hyperexcitability expands on 
the theory of vasoconstriction/vasodilatation. According to the theory of 
hyperexcitability, the brains of migraine sufferers are more sensitive to normal triggers, 
such as stress.  The frequency of migraines depends on the level of excitability. An 
external trigger may stimulate sudden constriction of the blood vessels in the brain 
resulting in the onset of a migraine headache. It is theorized that the cause of this 
excitability is due to abnormal brain chemistry, specifically in the relationship between 
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calcium and magnesium. Calcium flows from the extracellular fluid to the intracellular 
space during periods of nerve excitability resulting in vasoconstriction. In theory 
anything that blocks the flow of calcium or restores the balance of magnesium to calcium 
would be helpful in mitigating migraine. Some studies have shown that calcium channel 
blockers can successfully prevent migraine attacks due to blocking the flow of calcium 
into cells (8). Another theory proposes that there is a derangement of serotonin 
metabolism and an excess of neurotransmitters. During migraine, serotonin levels are 
depressed in the brain.  Triptans selectively stimulate certain serotonin receptors and have 
been shown to reduce the symptoms of migraine (9). This theory is supported by the fact 
that melatonin, secreted by the pineal gland along with serotonin, is also reduced during 
migraine.  This suggests that the pineal gland is depressed in migraine patients (10).  High 
levels of steroid hormones, primarily estrogen, can interact with the serotonin transport 
system. This further compromises the availability of serotonin. Other parts of the nervous 
system are also implicated in migraines. The sympathetic nervous system is responsible 
for many functions including increasing the contractility of smooth muscle and increasing 
the heart rate. Many of the reported factors that trigger migraine, such as stress and 
hormonal changes, also act on the sympathetic nervous system (9). Similarly, drugs that 
mimic or enhance norepinephrine may alleviate migraine (9).  Some evidence implicates 
steroid hormonal imbalances in migraine. Reports by women note that their migraine 
attacks occur in connection with their menses.  Abnormal hormone levels have been 
suspected as closely associated with migraine headaches.  As previously discussed, 
occasionally a small percentage of migraine sufferers will fall into the category of 
chronic daily headaches.  Current diagnostic criteria used to define CDH were published 
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by the International Headache Society in 2004. According to these criteria, primary 
chronic daily headache (CDH) is defined as daily or almost daily migrainous headache 
that occurs for more than 15 days a month, for greater than 3 months, and has no 
structural or infectious causes.  Associated symptoms of nausea, vomiting, photophobia, 
and phonophobia may be less frequent in chronic migraineur. The pathogenesis of 
chronic daily headache is not well understood, and some believe that it is due to a central 
mechanism involving an alteration in serotonergic and monoaminergic pathways to the 
brainstem and hypothalamus (14).  Chronic daily headaches have been associated with an 
increased frequency of primarily psychiatric comorbid conditions such as depression, 
anxiety, bipolar disorders, panic attacks, oromandibular dysfunction, stress, and drug 
overuse. 
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Management 
Acute treatment of migraine headaches involves the use of medications intended to 
relieve the symptoms of attacks when they occur. Migraine headache preventative efforts 
involve the use medications taken daily to reduce the number of attacks and lessen the 
intensity of pain. Some patients may respond to alternative treatment such as lifestyle 
changes, relaxation techniques, acupuncture, exercise, proper rest and dietary 
modification. Typically these are referred to as complementary treatment and may help 
avoid the triggering of attacks.  Medication overuse, commonly known as rebound 
headache, can have a significant influence on initiation of migraine headaches (4).  
Standard medical approach to managing migraine headaches include preventative or 
prophylactic measures, trigger management, abortive measures and pain management of 
the headache once it occurs.  Typically preventative measures have relied on the use of 
medications that were never intended to treat headaches.  These include beta blockers, 
calcium channel blockers, Methylsergide or Divalproex Sodium.   Beta-blockers, 
primarily Propranolol, are one of the most commonly prescribed prophylactic treatments 
for Migraine and are considered to be an effective preventive treatment.   Calcium 
channel blockers are thought to play a role in migraine prevention by affecting blood 
vessel constriction as previously discussed.  Methysergide is thought to block the 
inflammatory and vessel-constricting effects of serotonin. Because of potential side-
effects, Methysergide is generally used only on select patients. Some of the known 
potential side effects include retroperitoneal fibrosis which may be severe but 
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uncommon. Other severe but uncommon side effects include pleural fibrosis and 
subendocardial fibrosis as well as an increased risk of left-sided cardiac valve 
dysfunction (5).  Because of the potential severity of these side effects, Methysergide 
requires a four to six week drug hiatus every six months.  Divalproex Sodium was 
originally developed for Epilepsy.  It is typically prescribed in smaller doses to treat 
migraine headaches to reduce the potential side effects.  Management of migraine 
triggers are effective if the trigger is known and can reasonably be avoided.  Triggers are 
different from person to person.  Some examples of reported triggers include changes in 
weather or air-pressure, bright sunlight, glare, fluorescent lights, chemical fumes, 
menstrual cycles, and certain foods such as processed meats, red wine, beer, dried fish, 
broad beans, fermented cheeses, aspartame, and MSG.  Once the prodromal phase of the 
migraine occurs and the headache is imminent, abortive measures may be initiated.  
Abortive medications are used to relieve the severity, duration and associated symptoms 
of the migraine headache. They are recommended to taken as early as possible in an 
attack.   Cerebral vasoconstrictor abortive agents were formulated specifically for 
migraine headaches. They may be administered by subcutaneous, oral, rectal, or 
intramuscular means. Some of the common medications include ergotamine tartrate or 
Dihydroergotamine, Sumatriptan, Naratriptan, Rizatriptan, Zolmitripan, Electriptan, 
Frovatriptan and Isometheptene mucate. The nonvasoconstrictive abortive agent 
Butorphanol tartrate may be administered by injection or nasal spray. Emergency 
departments commonly use narcotic injections in combination with Promenthazine or 
Hydroxyzine for nausea.  These can offer an option if other measures fail or are not 
appropriate for comorbid conditions such as heart disease or other medical condition that 
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would contraindicate their use.  Once the headache starts, pain management may include 
narcotic analgesics.  These act on the nervous system receptors and alter the patient's 
perception of pain. These drugs may relieve pain, however they may be addictive and 
such usage should be done in an appropriate manner. Common narcotic medications 
include  Butalbital with Codeine, Codeine, Acetaminophen and Oxycodone 
hydrochloride, Meperidine hydrochloride, acetaminophen and codeine, Hydrocodone 
bitartrate and acetaminophen or methadone.  Though normally ineffective for relief of 
migraine headaches, NSAIDs (non-steroidal anti-inflammatory drugs) act by inhibiting 
blood vessel inflammation. These medications include Naproxen, Ibuprofen and 
Ketorolac.  Most are readily available over the counter in non prescription doses which 
makes them accessible to the general public.  Many migraine headache sufferers take 
these OTC medications in inappropriate doses in a desperate attempt to relieve a 
debilitating painful condition.  Some migraineurs attempt to manage mild to moderate 
attacks at home by using a variety of techniques which include using a cold compress to 
the area of pain, resting with pillows comfortably supporting the head or neck in a room 
with little or no sensory stimulation (light, sound, odors), avoiding stressful surroundings, 
sleeping or consuming a moderate amount of caffeine.  Other alternative treatments 
include but are not limited to acupuncture, biofeedback, manipulation, massage and 
nutritional (herbs, vitamins, minerals).  Lifestyle and home remedies, as described by the 
Mayo Clinic staff on their web page regarding migraines, mayoclinic.com, can include 
muscle relaxation exercises, proper rest and keeping a headache diary to help learn more 
about what triggers the migraines and what treatment is most effective.  They also 
indicate that Botulinum toxin type A is sometimes used for treatment of chronic 
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migraines. They state that studies have had mixed results with respect to effectiveness but 
that some headache specialists believe that it can be helpful for some people. Injections 
are made in muscles of the forehead and neck. When this is effective, the treatment 
typically needs to be repeated every three months.  
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Botulinum Neurotoxin Overview 
Botulinum toxin is a neurotoxic protein produced by the bacterium Clostridium 
botulinum, and is held to be the most toxic substance known to mankind (16) with an 
LD50 of roughly 0.005–0.05 µg/kg.  The flaccid muscular paralysis can be fatal in cases 
of botulism.  Ironically, this property is intentionally used as an advantage in medical 
treatments.  The toxins are injected into the muscles at different sites on the body 
resulting in temporary paralysis with effects lasting from 3 to 9 months. The toxin is a 
microbial product synthesized by the anaerobic, gram-positive, spore forming bacteria 
ubiquitously found in the soil. Historically Botulinum toxin has been considered a 
byproduct of the bacteria resulting in spoiled food. The Botulinum toxin's most 
significant adverse health effect is its prevention of neurotransmission causing paralysis. 
Death occurs from Botulism primarily as a result of paralysis of the respiratory muscles 
leading to respiratory failure (19).  German physician Justinus Kerner (1786-1862) first 
developed the idea of a possible therapeutic use of Botulinum toxin which he called 
"sausage poison”.  In 1928, Dr. Herman Sommer, at the University of California, San 
Francisco, first isolated in purified form Botulinum toxin type A (BoNT-A) as a stable 
acid precipitate. In the 1950s, Dr. Vernon Brooks discovered that when BoNT-A is 
injected into a hyperactive muscle, it blocks the release of acetylcholine from motor 
nerve endings. Work with Botulinum toxin type A as a therapeutic agent to treat human 
disease began in the late 1960s through the collaboration of Alan B. Scott, MD, of the 
Smith-Kettlewell Eye Research Foundation and Edward J. Schantz, PhD, director of food 
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microbiology and toxicology at the University of Wisconsin. This is when Botulinum 
toxin type A was first considered as a powerful therapeutic agent to treat symptoms of 
neurological disorders rather than an agent of human sickness and disease.  In 1980, Dr. 
Alan B. Scott, of Smith-Kettlewell Eye Research Institute, used Botulinum neurotoxin-A 
for the first time in humans to treat strabismus.  In December 1989, BTX-A (BOTOX) 
was approved by the FDA for the treatment of strabismus, blepharospasm, and hemifacial 
spasm in patients over 12 years old. Although the effect had been observed by a number 
of independent groups, the cosmetic effect of BoNT-A was initially described by 
ophthalmologist Jean Carruthers and dermatologist Alastair Carruthers working in 
Vancouver, Canada.  The FDA announced the approval of BOTOX® Cosmetic on April 
15, 2002 as a treatment to temporarily improve the appearance of moderate to severe 
frown lines between the eyebrows referred to as glabellar lines.  BoNT is broken into 7 
neurotoxins labeled types A, B, C [C1, C2], D, E, F, and G.  They are all antigenically 
and serologically distinct but structurally similar. Human botulism is primarily caused by 
types A, B, E, and F. Types C and D are only toxic in animals. The toxin is a zinc 
dependent protease that cleaves one or more of the fusion proteins by which neuronal 
vesicles release acetylcholine (Ach) into the neuromuscular junction. It acts preferentially 
on peripheral cholinergic nerve endings to block Ach release (18).  The details of BoNT 
mechanism are described by Takamizawa K, Iwamori M and Kozaki S, et al.  The BoNT 
molecule is synthesized as a single chain and then cleaved to form the dichain molecule 
with a disulfide bridge. The light chain acts as a zinc endopeptidase similar to tetanus 
toxin with proteolytic activity located at the N-terminal end. The heavy chain provides 
cholinergic specificity and is responsible for binding the toxin to presynaptic receptors.  It 
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also promotes light chain translocation across the endosomal membrane. Botulinum toxin 
acts by binding presynaptically to high affinity recognition sites on the cholinergic nerve 
terminals.  This results in decreased the release of acetylcholine causing a neuromuscular 
blocking effect. Specifically, Botulinum toxin cleaves SNARE proteins which are 
involved with fusing synaptic vesicles to the plasma membrane. Cleaving of SNARE 
proteins inhibits the release of acetylcholine at the neuromuscular junction leading to 
inhibition of neurotransmission. Cleaving SNARE proteins creates a nonfunctional 
SNARE complex disrupting calcium influx and fusion is disrupted.   Increasing the 
calcium concentration in the synaptic terminal may diminish the effects of Botulinum 
toxin.  According to de Paiva A, Meunier FA, Molgó J, et al, recovery occurs through 
proximal axonal sprouting and muscle reinnervation by formation of a new 
neuromuscular junction. BoNT-A and BoNT-E cleave synaptosome associated protein 
(SNAP-25), a presynaptic membrane protein required for fusion of neurotransmitter-
containing vesicles (17).   When BoNT-A is injected into a striate muscle, paresis occurs 
after two to five days and lasts from two to three months before it gradually starts to wear 
off.  When Botulinum Toxin is injected into a target tissue it is almost completely bound 
to the axon terminal (20).  However, when BoNT-A is applied to treat cervical dystonia, 
small fractions of the applied Botulinum toxin are distributed systemically and can be 
detected by increase of neuromuscular jitter in non injected muscles (21). When Botulinum 
Toxin-B is applied to treat cervical dystonia substantial systemic anticholinergic side 
effects can be clinically detected (18). Despite its systemic distribution, direct Botulinum 
Toxin effects on the CNS have not been reported. This is because Botulinum neurotoxin 
with its size of 150 KiloDalton does not penetrate the blood brain barrier. Apart from 
 15
systemic penetration Botulinum toxin could theoretically reach the CNS by retrograde 
axonal transport. Such retrograde axonal transport has been detected for Botulinum toxin 
with radioactively labeled Botulinum neurotoxin (22).  The Botulinum toxin was likely 
inactivated before it reached the CNS since the retrograde axonal transport was so slow. 
Transsynaptic transport was not observed. Botulinum Toxin action upon Renshaw cells 
was only demonstrated after intraspinal injection (23).  Effects of Botulinum Toxin on the 
neuromuscular synapse and on the muscle spindle organs can produce various indirect 
effects on the CNS. On the spinal level Botulinum Toxin produces reflex inhibition of 
alpha motoneurons by gamma motoneuron blockade and subsequent Ia/II afferent input 
suppression1(24,25).  Botulinum toxin may normalize altered reciprocal inhibition between 
flexor and extensor muscles in patients with upper limb dystonia (26).  A similar effect 
was also demonstrated in patients with essential tremor (27). EMG changes of the 
contralateral ocular muscles after injection of Botulinum toxin into the lateral rectus 
muscle also suggest central effects (28).  Botulinum toxin may also normalize altered 
intracortical inhibition at the supraspinal level (29) as well as altered somatosensory 
evoked potentials (30). Although Botulinum toxin can enhance some aspects of cortical 
activation it fails to improve the impaired activation of the primary motor cortex as seen 
in writer's cramp (31).  When Botulinum Toxin is used to treat painful muscle 
hyperactivity disorders frequently substantial pain relief is reported. Pain relief is usually 
attributed to the reduction of the muscle hyperactivity. However, formalin-induced pain 
in animals can be reduced by Botulinum toxin direct analgesic effect (32).  Substance-P is 
a neuropeptide involved in pain perception, vasodilatation and neurogenic inflammation.  
It has been shown to be blocked by Botulinum toxin together with acetylcholine in the 
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iris muscles of rabbits (33) as well as in cultured dorsal root ganglia neurons (34).  Direct 
Botulinum toxin effect is suggested due to this association of inhibition with a decrease 
of SNAP 25.  Botulinum Toxin induced suppression of substance-P has also be 
demonstrated in embryonic rat dorsal root ganglia neurons (35).  When different 
Botulinum toxin serotypes were tested, Botulinum Toxin-A produced the strongest 
substance-P suppression (35).  Botulinum Toxin has also been shown to suppress the 
release of glutamate, another neurotransmitter involved in nociception, in the periphery 
and in the dorsal horn (36).  This confirmed earlier findings of Botulinum toxin induced 
inhibition of glutamate release from cerebrocortical synaptosomes (37).  The release of 
noradrenalin in PC12 cells (38), used as a model system for neuronal differentiation, and 
calcitonin gene related peptide in autonomic vascular nerve terminals (39) could also be 
reduced by Botulinum Toxin suggesting additional possible mechanisms for Botulinum 
Toxin effects on pain transmission (40).   
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Clinical uses for Botulinum Neurotoxin 
According to the FDA website, www.fda.gov, information regarding approved 
preparations of Botulinum toxin products is limited to 3 preparations of Botulinum 
neurotoxin type A.  They are marketed by 2 companies under the labels Botox, Botox 
Cosmetic and Dysport.  The only listed indications for use according to the FDA site are 
for cervical dystonia, severe primary axillary hyperhidrosis, strabismus, blepharospasm, 
and temporary improvement in the appearance of moderate to severe glabellar lines.  
Considerations for health care professionals section states that a boxed warning has been 
added to the prescribing information to highlight that Botulinum toxin may spread from 
the area of injection to produce symptoms consistent with botulism. Symptoms such as 
unexpected loss of strength or muscle weakness, hoarseness or dysphonia, dysarthria, loss 
of bladder control, trouble breathing, trouble swallowing, double vision, blurred vision 
and drooping eyelids may occur.  Swallowing and breathing difficulties can be life 
threatening and there have been reports of deaths related to the effects of spread of 
Botulinum toxin.  It also states that clinical doses expressed in units are not comparable 
from one Botulinum toxin product to the next. Units of one product cannot be converted 
into units of another product thus Botulinum toxin products differ from one another in 
dose units, names, and dosing and are not interchangeable.  In November 2001, Health 
Canada approved Botox injections to reduce spasticity that can occur after a stroke.  
Allison Brashear, MD, professor and chair of the Neurology department at Wake Forest 
University Baptist Medical Center in Winston Salem, N. C., directed the first major study 
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in 2002 on the use of Botox for post stroke muscle spasticity (41).  The results were 
published in the New England Journal of Medicine. In that multi-center study, half of the 
126 patients received Botox and the other half took a placebo. 62% of the Botox group 
reported improvement in the area they desired as opposed to just 27% of the placebo 
group. In that study, patients received just one injection.  In 2005 at the annual meeting of 
the American Association of Physical Medicine in Philadelphia, Dr. Brashear presented 
the findings of the first long-term study of the repeated use of Botulinum toxin type-A for 
the treatment of post stroke spasticity.   The study focused on 279 patients at 35 
rehabilitation centers in Indiana over a 1 year period.  The research was funded by the 
company that manufactures Botox, Allergen Inc.  The participants in the study had hand, 
wrist or elbow spasticity. Up to five doses were given to targeted muscles in the wrist, 
elbows and fingers.  Six weeks into the study researchers discovered a notable 
improvement in patients’ muscle tone from the onset of treatment.  Improvement was 
graded in four areas consisting of pain, hygiene, dressing and limb posture.  At least half 
the participants by the end of the study reported that they had improved by one point in 
the area they deemed most significant.  Despite these results, treatment for muscle 
spasticity remains an off label use.  Several other off label uses of Botulinum toxin-A has 
been and are currently used in practices of various subspecialties.  Some of the more 
common off label uses include low back pain, dystonia, laryngeal spasm, hemifacial 
spasm and migraine headaches.  Since the nature of this study involves treatment using 
Botulinum toxin-A for migraine headaches, I will focus on information to that use.   
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Supportive Studies 
Chronic daily headaches (CDH) are a heterogeneous group of headache disorders 
occurring on at least 15 days per month that, according to population studies, affects 4% 
to 5% of the general population worldwide (42-45).  Chronic migraine is in the subset of the 
CDH disorders.  Chronic migraine was first characterized by Silberstein and Lipton.  By 
definition it includes head pain occurring on 15 or more days per month, headache 
duration of 4 or more hours and increasing headache frequency with decreasing symptom 
severity over a 3-month period (46-47).  The two most common forms of primary, long 
duration CDH disorders are chronic (transformed) migraine and chronic tension 
headaches, with most subclassified as transformed migraine (48-50).  While most CDH 
patients are categorized as having transformed migraine others may have chronic tension 
type headache (51-52). Transformed migraine may also be associated with medication 
overuse headache (53,54).  As indicated previously, the current standard treatment for 
migraine headaches includes primarily medications designed to abort an imminent 
headache or manage the pain associated with the headache once it starts.   Chronic 
migraine is often both common and resistant to treatment even with prophylactic 
medications known to be effective in patients with episodic migraine headaches (55).  
Medications used to treat chronic migraines include simple analgesics as well as 
prophylactic medications that were originally designed to treat other conditions such as 
depression, hypertension, and seizures.  Practitioners often struggle with decisions on 
how to best manage patients who present with persistent migraine headaches that have 
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shown little lasting response to standard medication regimens and are either utilizing 
excessive amounts of prescription medications or showing poor response to medications 
prescribed with no other explanation as to why their headaches persist.  The disability 
and impact associated with this disorder is substantial and touches almost every aspect of 
the patient's life. These patients experience significantly diminished health-related quality 
of life.  Mental health as well as physical, social, and occupational functioning may also 
be impaired (56).  Many alternative methods of management as previously listed also have 
had mixed results.  Interest in the use of botulinum toxin-A was first generated following 
an observation by practitioners using the commercial preparation for cosmetic purposes 
following the initial approval by the FDA.  When doing procedures involving injections 
to remove glabellar lines, patients who had previously experienced frequent migraine 
headaches reported a reduction in the frequency and intensity of headaches.  Since 1992, 
Botulinum toxin-A had been used in purified and diluted form to temporarily paralyze the 
Corrugator and Procerus muscles that bring the eye brows together to eliminate wrinkles 
in this region.  The practice of injecting the area with Botulinum toxin-A in the upper 
third of the face for treatment of cosmetic frown lines in patients who coincidentally 
suffered from Migraines, resulted in  the reported unexpected benifit of migraine relief 
(57).  During the November 2-5, 2000 American Society of Dermatologic Surgery meeting 
, Richard Glogau, MD, University Of California, San Francisco professor of dermatology 
presented a study that he performed at UCSF.  He reported that 75 % of patients in his 
case study experienced four to six months of Migraine relief following injections of 
Botulinum toxin-A into muscles of the face and head. Glogau's small study of 24 patients 
added weight to previous reports that Botulinum toxin-A can relieve Migraines.  
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Following this opportune discovery, Dr. Glogau and other researchers began to evaluate 
injection points and dosages that could alleviate Migraines.  Dr. Glogau's results 
indicated that Botulinum toxin-A injected into the muscles of the brow, eyes, forehead, 
side of the head and back of the head near the neck provoked sometimes immediate 
migraine relief and provided benefit for up to six months. The dosage of Botulinum 
toxin-A in his case studies averaged 80 units per patient (57).  Unfortunately most of the 
data at that time consisted of case reports and meeting abstracts. There were no published 
randomized double-blind trials that demonstrated safety and efficacy of Botulinum toxin-
A for treatment of migraines.  There were only two previous studies which were 
presented at the 1999 meeting of the American Association for the Study of Headache 
(currently the American Headache Society). The first study was reported by researchers 
at the Michigan Head Pain and Neurological Institute in Ann Arbor and Michigan State 
University.  The study involved a procedure using a one time dose of 25 units of 
Botulinum toxin A injected into the muscles of the brow, forehead and side of the head.  
The results of this study reflected a reduction in the frequency of Migraines, the severity 
of pain, vomiting, and the use of pain medications for up to three months. Treatment with 
75-units resulted in migraine relief but also elicited undesirable side effects like eyelid 
drooping.  In the second study, reported by researchers at the University of California, 
Los Angeles, 51% of 96 patients reported complete improvement of their Migraine pain 
(57).  Other researchers developed an interest and proceeded to set up their own studies 
following these reports of migraine relief using Botulinum toxin-A.  In 2004, Stafford 
Conway, M.D. et al, undertook an open label study to evaluate the safety and utility of 
Botulinum toxin type-A injection therapy for patients with chronic migraine who 
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previously had failed to respond to at least three prophylactic medications.  The study at 
the University of South Alabama Headache Center in Mobile, Al. involved a total of 59 
patients.  An inclusion criterion was that the patient had previously failed at least three 
adequate trials of prophylactic medications known to be effective in treating episodic 
migraine.  All participating patients were asked to complete a Migraine Disability 
Assessment (MIDAS) questionnaire and to keep a headache diary for the month 
preceding Botulinum toxin type-A administration.  All patients received 25 units of 
Botulinum toxin type-A per the fixed frontal-temporal site protocol published by 
Silberstein et al (58).  Participating patients were asked to return for follow-up 6 weeks 
after Botulinum toxin type-A treatment and present their headache diary including any 
perceived side effects.  Their report included only a descriptive analysis of the results. A 
“positive response” was defined to be a 50% or greater reduction in headache days per 
month over the last 30 days of the follow-up period relative to the patient’s baseline 
status. Other outcome variables analyzed included subjective response (“much better,” 
“somewhat better,” “same,” or “worse”) and functionally incapacitating headache days 
per month over the last 30 days of the follow-up period relative to the 30 days 
pretreatment.  Their results showed a 41% positive response rate however their 
conclusion stated that “Based on our observations and results from other published 
reports, we offer for speculation the possibility that the current uncertainty regarding the 
efficacy of BoNT-A for prevention or suppression of migraine may reflect a type II error; 
that is, even the large-scale studies performed to date have involved too few patients 
overall and included too many subjects predestined to fail.”  One of the most frequently 
referenced studies was a multicenter trial funded by Allergan Inc., the makers of Botox 
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(BoNT-A ) which was used in the study.  This was one of the first randomized, double-
blind, placebo-controlled study of Botulinum toxin type-A in patients with diagnostic 
criteria of CDH and was conducted from July 6, 2001, through November 7, 2003, at 28 
North American study centers.  The study was headed by Stephen D. Silberstein, M.D. in 
cooperation with the Bonta-039 Study Group.  The study was a randomized, double-
blind, placebo-controlled, parallel group clinical study of 3 fixed-dose treatments of 
Botulinum toxin type-A compared with placebo in the treatment of patients with CDH.  
Inclusion criteria for the study included men and women aged 18 to 65 years who 
experienced headaches on more than 15 days during a 30-day baseline screening period. 
Headaches could include any combination of migraines with or without aura, migrainous 
headache, probable migraine, and/or episodic or chronic tension-type headaches.  
Included were long-term prophylactic headache medications however they had to be 
stable with no change in dose or dosing regimen for at least 3 months immediately before 
the baseline period.  Patients were excluded from the study if they had any medical 
condition such as neuromuscular disorders or used any agent that might expose them to 
risk if they received Botulinum toxin type-A, had an infection or skin problem at any of 
the injection sites, had a known allergy or sensitivity to the study medication or to its 
components as well as other exclusions listed in the study (60).  This was a double-blind 
study and neither the investigator nor the patient knew which treatment was given at day 
0, day 90, and day 180.  Among 1200 screened patients, 702 (mean age 43.4 years with 
82.9% female) were enrolled, entered into the placebo run-in period, and subsequently 
randomized to active treatment or placebo at day 0.  At the end of the placebo run-in 
period, of 702 patients, 538 were classified as placebo nonresponders and 164 as placebo 
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responders.  Subsequently, patients within each group were randomized to receive 
Botulinum toxin type-A at 225 U (n=182), 150 U (n=168), 75 U (n=174), or placebo 
(n=178). The primary efficacy end point was the mean change from baseline in the 
frequency of headache-free days for the 30-day period ending on day 180 for the placebo 
nonresponder group. A secondary efficacy end point was the proportion of patients with a 
decrease from baseline of 50% or more in the frequency of headache days per 30-day 
period at day 180 for the placebo nonresponder group. Other variables evaluated per 30-
day period included the frequency of any type of headaches, the proportion of patients 
with a decrease from baseline of 50% or more headaches, the frequency of migraine 
headaches of any severity, the proportion of patients with a decrease from baseline of 
50% or more in migraine headaches, the proportion of patients with a decrease from 
baseline of 2 or more migraine headaches, and the frequency of moderate to severe 
migraine headaches.  Although the primary efficacy end point was not met, Botulinum 
toxin type-A treatment in this trial showed a significant difference from placebo in some 
analyses.  At day 240, the decrease in headache frequency was significantly greater for 
the Botulinum toxin type-A 225 U and 150 U groups compared with placebo.  The 
placebo response was higher than expected but a greater percentage of patients in the 
placebo group used pain medications for acute headache throughout the study, thereby 
confounding the results (60).  A later study was published in Headache April 2005 by 
Mathew NT, Frishberg BM, Gawel M, Dimitrova R, Gibson J, Turkel C; BOTOX CDH 
Study Group.  This was an 11-month, randomized double-blind, placebo-controlled study 
of Botulinum toxin type-A for the treatment of patients aged 18 to 65 years old with 16 or 
more headache days per 30 days conducted at 13 North American study centers. The 
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primary efficacy measure was the change from baseline in the frequency of headache-free 
days in a 30-day period for the placebo nonresponder group at day 180, the chosen 
efficacy time point. The secondary efficacy measure was the proportion of patients with a 
decrease from baseline of 50% or more in the frequency of headache days per 30-day 
period for the placebo nonresponder group at day 180.  The change from baseline in the 
frequency of headaches per 30-day period, the proportion of patients with a decrease 
from baseline of 50% or greater in the frequency of headaches per 30-day period, acute 
medication use, and adverse events were also assessed.  355 patients, with a mean age of 
43.5 years and 84.5% female, were enrolled and randomized (59).  At day 180, placebo 
nonresponders treated with Botulinum toxin type-A had an improved mean change from 
baseline of 6.7 headache-free days per 30 day period compared to a mean change from 
baseline of 5.2 headache-free days for placebo-treated patients. The between group 
difference was not statistically significant but revealed 1.5 headache-free days in favor of 
Botulinum toxin type-A treatment. There was a statistically significant difference was 
observed at day 180 endpoint for the secondary efficacy measure. A significantly higher 
percentage of Botulinum toxin type-A patients had a decrease from baseline of 50% or 
greater in the frequency of headache days per 30-day period at day 180 (32.7% vs. 
15.0%, P=.027).  The mean change from baseline in the frequency of headaches per 30 
day period at day 180 was -6.1 for Botulinum toxin type-A patients vs. -3.1 for the 
placebo patients (P=.013). Only 4 of 173 Botulinum toxin type-A patients (2.3%) 
discontinued the study due to adverse events (59).  From the data collected in this study, 
the researchers concluded that Botulinum toxin type-A treatment resulted in patients 
having, on average, approximately seven more headache free days compared to baseline. 
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Although at the primary time point the Botulinum toxin type-A treatment resulted in a 1.5 
between-group difference compared to placebo and the difference was determined to be 
not statistically significant.  The treatment met secondary efficacy outcome measures, 
including the percentage of patients experiencing a 50% or more decrease in the 
frequency of headache days in addition to statistically significant reductions in headache 
frequency.  A follow up study using a subgroup analysis of the 11month, randomized 
double-blind, placebo-controlled study of Botulinum toxin type-A was later published in 
April of 2005.  The objective of this study was to assess the efficacy and safety of 
Botulinum toxin type A for the prophylaxis of headaches in patients with chronic daily 
headache (CDH) without the confounding factor of concurrent prophylactic medications. 
This investigation involved data for patients who were not receiving simultaneous 
prophylactic headache medication and who constituted 64% of the full study population.  
This placebo-controlled study consisted of a 30 day baseline period during which 
headache frequency was monitored along with a 30 day single blind placebo run in period 
during which response to placebo was determined and a 9 month double blind treatment 
period during which patients received three treatment cycles (Botulinum toxin type-A or 
placebo) separated by 90 days (56).  228 patients from the original study group were not 
taking prophylactic medication and were included in this analysis.  117 patients received 
Botulinum toxin type-A and 111 patients received placebo injections. Mean age was 42.4 
± 10.90 years with a mean frequency of headaches per 30 days at baseline of 14.1 for the 
Botulinum toxin type-A group and 12.9 for the placebo group ( P = .205). After two 
injection sessions, the maximum change in the mean frequency of headaches per 30 days 
was -7.8 in the Botulinum toxin type-A group compared with only -4.5 in the placebo 
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group ( P = .032).  There was a statistically significant between group difference of 3.3 
headaches. The between group difference favoring Botulinum toxin type-A treatment 
continued to improve to 4.2 headaches after a third injection session ( P = .023). 
Botulinum toxin type-A treatment at least halved the frequency of baseline headaches in 
over 50% of patients after three injection sessions compared to baseline. Statistically 
significant differences between Botulinum toxin type-A and placebo were evident for the 
change from baseline in headache frequency and headache severity for most time points 
from day 180 through day 270. Only 5 patients (4 patients receiving Botulinum toxin 
type-A treatment; 1 patient receiving placebo) discontinued the study due to adverse 
events and most treatment related events were transient and mild to moderate in severity. 
The researchers concluded that Botulinum toxin type-A is an effective and well-tolerated 
prophylactic treatment in migraine patients with CDH who are not using other 
prophylactic medications (56).  
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Controversy 
Although there have been well done studies that have indicated that BoNT has shown 
promise in cases of refractory migraine headache treatment and prophylaxis, not 
everyone is convinced that the evidence is worthy of FDA approval for routine use.  The 
primary issue with acceptance of research results showing efficacy of Botulinum toxin 
type-A in the treatment of migraine headaches is that the largest studies were funded by 
Allergan, the company that produces BoNT.  "Official Disability Guidelines" and "ODG" 
are trademarks of Work Loss Data Institute.  The “Official Disability Guidelines” uses a 
comprehensive annual update process based on scientific medical literature review, 
survey data analysis, and expert panel validation to determine strength of 
recommendation regarding medical procedures.  It was designed for use by providers, 
employers, insurance claims professionals, and state workers’ compensation authorities.  
The large claims review centers use the ODG as a guide to authorize or deny requests for 
authorization of procedures on enrolled workers.  According to the ODG, “the evidence 
is mixed for migraine headaches. This RCT found that both Botulinum toxin type-A 
(BoNT-A) and Divalproex sodium (DVPX) significantly reduced disability associated 
with migraine, and Botulinum toxin type-A had a favorable tolerability profile compared 
with DVPX. (Blumenfeld, 2008).  In this RCT of episodic migraine patients, low-dose 
injections of BoNT-A into the frontal, temporal, and/or glabellar muscle regions were not 
more effective than placebo (Saper, 2007). Botulinum neurotoxin is probably ineffective 
in episodic migraine and chronic tension-type headache. (Naumann, 2008)”.  In the 
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referenced study by Blumenfeld, comparative evaluation of the efficacy and safety of 
Botulinum toxin type A and Divalproex sodium as prophylaxis in reducing disability and 
impact associated with migraine was done.  This was a randomized, double-blind, single-
center prospective study. Fifty-nine patients received either Botulinum toxin type-A 100 
U/placebo-DVPX bid or placebo- Botulinum toxin type-A /DVPX 250 mg bid. 
Botulinum toxin type-A /placebo injections were given at Day 0 and at Month 3. Patients 
were evaluated at Months 1, 3, 6, and 9.  Both treatments showed significant 
improvements in migraine disability scores and reductions in headache days and 
headache index. A trend of decreased headache severity was observed with Botulinum 
toxin type-A. A greater percentage of DVPX patients reported adverse events possibly 
related to treatment (DVPX 75.8% vs. Botulinum toxin type-A 50%, P = .04) and 
discontinued because of adverse events (DVPX 27.6% vs Botulinum toxin type-A 3.3%, 
P = .012) (61).   The second referenced study was done by Saper et al in 2007.  This was a 
randomized, double-blind, placebo-controlled study of 232 patients with a history of four 
to eight moderate to severe migraines per month, with or without aura. Patients were 
randomized to placebo or one of four Botulinum toxin type-A groups that received 
injections into different muscle regions in the frontal (10 U), temporal (6 U), glabellar (9 
U), or all three areas (total dose 25 U). For 3 months following a single treatment, 
patients recorded migraine-related variables in a daily diary. Their results indicated that 
Botulinum toxin type-A and placebo produced comparable decreases from baseline in the 
frequency of migraines (P > or = 0.411). In general, no statistically significant differences 
were observed for any efficacy variable. The overall rates of adverse events or treatment 
related adverse events were similar among the groups.  They concluded that low dose 
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injections of Botulinum toxin type-A into the frontal, temporal, and/or glabellar muscle 
regions were not more effective than placebo (62).  The third referenced study was done by 
Naumann et al in 2008.  A literature search was performed including MEDLINE and 
Current Contents for therapeutic articles relevant to Botulinum toxin type-A and the 
selected indications.  They concluded by their research that Botulinum toxin type-A is 
probably ineffective in episodic migraine and chronic tension-type headache. There is 
presently no consistent or strong evidence to permit drawing conclusions on the efficacy 
of Botulinum toxin type-A in CDH mainly transformed migraine (63).   
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Recent Data 
In September 2008, Allergan announced that it had completed analyzing data of two 
Phase III clinical trials designed to evaluate the use of botulinum toxin type-A for the 
prophylactic treatment of headache in adults suffering from chronic migraine as defined 
by the criteria of chronic daily headaches.  In the two Phase III clinical trials, patients 
were randomly assigned for treatment with botulinum toxin type-A or placebo injections 
every 12 weeks. The primary analysis was performed at week 24 following 2 treatment 
cycles. The two major efficacy measures evaluated in the trials were change from 
baseline in the number of headache episodes and number of headache days occurring in 
the 28 day period preceding the week 24 time point. In the first Phase III clinical trial, 
Allergan prospectively selected number of headache episodes as the primary endpoint for 
evaluation. Number of headache days was selected as the major secondary endpoint. 
Results from the first Phase III clinical trial indicated that although both the botulinum 
toxin type-A and placebo treatment groups showed a statistically significant improvement 
from baseline.  There was no significant difference in the reduction of number of 
headache episodes between patients receiving botulinum toxin type-A and placebo. As in 
previous study outcomes, the study did show a decrease in number of headache days 
which is the FDA's preferred efficacy measure.  This was significantly greater in patients 
receiving botulinum toxin type-A as compared to patients receiving placebo (p=0.006). 
The decrease in number of migraine or probable migraine days was also found to be 
significantly greater in patients treated with botulinum toxin type-A as compared to 
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patients receiving placebo (p=0.002).  Based on the data from the first Phase III clinical 
trial, the primary endpoint for the second Phase III study was prospectively changed to 
number of headache days, with number of headache episodes changed to a secondary 
endpoint, before the data were unmasked. In the second Phase III study, the primary 
endpoint and key secondary endpoints showed statistically significant benefit of 
botulinum toxin type-A treatment over placebo injections. The patients treated with 
botulinum toxin type-A demonstrated a significantly greater decrease in both number of 
headache days (p<0.001) and number of headache episodes (p=0.003). As in the first 
Phase III trial, the second study also showed a decrease in number of migraine or 
probable migraine days that was significantly greater in patients treated with botulinum 
toxin type-A as compared to placebo (p<0.001).  In both Phase III clinical trials, 
botulinum toxin type-A treatments were well tolerated in patients suffering from chronic 
migraine. Both studies used quality of life evaluation using the validated Headache 
Impact Test which is a migraine management tool to help identify the severity and 
frequency of migraine headaches.  Patients receiving botulinum toxin type-A treatments 
scored statistically significantly higher improvement in quality of life when compared to 
patients receiving placebo injections (p<0.001 in both studies).  Allergan is in the process 
of gaining approval from the FDA to add the use of botulinum toxin-A for treatment of 
chronic migraine headaches based on this new data.  Other recent smaller studies 
sponsored by Allergan produced similar results (64).   
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MIDAS Questinnaire 
Despite the lack of support by the FDA, numerous practitioners as including those in 
some VA hospitals perform botulinum toxin-A injections for prophylactic treatment of 
refractory chronic megraine headaches.  Both the Neurology Department at Bay Pines 
Hospital in St. Petersburg, Fl and the Neurology Department’s Pain Management Clinic 
at James A Haley VA Hospital in Tampa, Fl provide this service.   From observation and 
evaluation of the patients undergoing the procedure, it appeared that there was a general 
positive response to the treatment and overall patient satisfaction.  Unfortunately there 
was no documentation to quantitate the effect on the patient’s improvement in lost work 
days, ability to perform activities of daily living, increase or decrease in medication use 
as well as cost difference pre and post treatment and effect on activities of daily living.  
One of the tools for evaluation of the severity of a patient’s disability due to the effects of 
migraine headaches is the Migraine Disability Assesment (MIDAS) questionairre.   The 
MIDAS questionnaire was put together to help measure the impact migraine headaches 
have on the patient’s life over the 3 months prior to the interview by the physician 
administering it.  The primary intent was to assess headache-related disability with the 
aim of improving migraine care. Headache sufferers answer five questions scoring the 
number of days in the past 3 months related to activity limitations due to migraine. The 
internal consistency, test–retest reliability, and validity of the questionnaire were assessed 
in separate population based studies of migraine sufferers.  The face validity, ease of use, 
and clinical utility of the questionnaire were evaluated in a group of 49 physicians who 
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independently rated disease severity and need for care in a diverse sample of migraine 
case histories.  The test–retest Pearson correlation coefficient for the total MIDAS score 
was approximately 0.8.  The MIDAS score was valid when compared with a reference 
diary based measure of disability.  The overall correlation between MIDAS and the diary 
based measure was 0.63. The MIDAS score was also correlated with physicians’ 
assessments of need for medical care (r = 0.69). From studies completed to date, the 
MIDAS Questionnaire has been shown to be internally consistent, highly reliable, valid, 
and correlates with physicians’ clinical judgment. These features support its suitability for 
use in clinical practice. Use of the MIDAS Questionnaire may improve physician patient 
communication about headache related disability and may favorably influence health care 
delivery for migraine patients (66).  Though the questionnaire has been validated by the 
American Academy of Neurology, it only gives information regarding the severity of the 
patient’s disability prior to care by the physician giving it.  The questionnaire does not 
address other issues such as direct or indirect cost of treating migraine headaches. In a 
2005 study done by Goldberg, migraine headaches were estimated to result in annual 
costs totaling as much as $17 billion in the United States (67).  Most of the direct costs are 
for outpatient services such as medications, office visits, emergency department visits, 
laboratory/diagnostic services and management of treatment side effects. Indirect costs 
from lost productivity in the workplace, as previously discussed, add substantially to the 
total. The Triptan class of drugs, used for abortive treatment, account for the greatest 
portion of medication costs. Research suggests that a stratified care strategy, with initial 
therapy based on the patient’s score on the MIDAS scale, is both clinically advantageous 
and more cost effective than stepped care strategies.  It should be noted that the Triptans 
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are not interchangeable and costs as well as clinical outcomes may vary with different 
agents in this class. Migraine prophylaxis is aimed at preventing frequent attacks and the 
development of a long term condition that often incurs heavy costs for abortive treatment, 
diagnostic services, and medical care. Agents approved for migraine prophylaxis include 
those listed in the above previous discussion. As with abortive therapy, costs vary widely 
among these prophylactic agents. Of the total annual cost associated with migraine and its 
treatment, roughly $1.5 billion goes to medication with Triptans accounting for $1.18 
billion with a mean cost per prescription of $160 (68).  Focusing specifically on migraine 
headaches, another study found that the annual cost to employers exceeded $14.5 billion, 
of which $7.9 billion was due to absenteeism, $5.4 billion to diminished productivity, and 
$1.2 billion to medical costs (69). A small open label trial of Botulinum toxin was 
conducted in 5 patients with migraine headaches that were unresponsive to conventional 
antimigraine medications. Evaluation was done after 1 year of injections at 3 month 
intervals.  The use of other migraine medications, as measured by the change in annual 
costs for other medications, had decreased from pretreatment levels. When the cost of the 
Botulinum toxin-A treatment itself was included, the total change in annual medication 
cost ranged from an increase of $648 to a decrease of $2717. All of the patients showed 
substantial clinical improvement with no reported adverse events.  Migraine symptoms 
typically decreased within a few days after each injection and maximal effects were noted 
over the 2 months after treatment (70).   A budgetary model provided a theoretical basis 
for predicting the cost outcome of selecting a given approach to migraine management.  
This model focused on the use of Botulinum toxin-A for prophylaxis in chronic migraine 
patients enrolled in a commercial managed care plan. The goal was to assess the impact 
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of a decision to allow the use of Botulinum toxin, in terms of cost effect for the plan as a 
whole. In calculating the cost of prophylaxis with Botulinum toxin, treatment at a 
standard interval of 3 months means that patients would receive 4 treatments per year. 
With the cost of each treatment given as $521.25, the yearly cost per patient is $2085, 
and the total yearly cost for 240 patients was $500,400.  The model did not account for a 
decrease in emergency department visits and hospitalization as a result of effective 
migraine prophylaxis which would be expected to augment the savings. Offsetting these 
costs would be a reduction in the amount of headache medication used for abortive 
treatment (70).  The final cost difference according to the study by Goldberg is that “in a 
plan with 1 million members, the savings associated with migraine prophylaxis using 
Botulinum toxin represents a change of less than 1 cent in overall cost per member per 
month ($76 360 divided by 12 million member months is a reduction of approximately 
$0.006 per member per month). The point, however, is not the insignificant change in 
cost, but that superior clinical outcomes in migraine management can be obtained with no 
increase in cost” (67).  According to the results of his study, headache related visits to the 
office and emergency department were reduced by 32% and 49% respectively. These 
reductions in headache related visits resulted in a net savings of $18,757. The greatest 
clinical improvements were seen in patients whose conditions were most severe at 
baseline (72). 
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Study Protocol 
Having an interest in the patient’s response to treatment with Botulinum toxin-A for 
migraine headache prophylaxis, this study utilized the questions in the MIDAS 
questionnaire with a slight modification to assess the patient’s post treatment response.  
In addition to the original 7 questions on the questionnaire, additional information 
regarding medication usage pre and post treatment as well as assessment of functional 
ability pre and post and number of treatments.  The study is designed as a cross sectional 
survey of patients currently undergoing the procedure at James A. Haley VA Medical 
Center Department of Neurology Pain Clinic and Bay Pines VA Hospital Department of 
Neurology outpatient clinic.  Inclusion criteria were patients age 21 – 65 who had 
received at least 2 treatments.  The patients currently undergoing the treatment with 
Botulinum toxin-A were pre screened by each department, on initial evaluation when first 
presenting to each clinic, to fit the criteria of chronic daily headaches as previously 
referenced and demonstrated a history of failure to other standard treatment protocols.  
Since the standard time between each treatment is typically 3-4 months, the questionnaire 
was to be administered over a 60 day period once initiated to prevent duplication of 
patient responses.  No personal health information was required on the questionnaire and 
exemption was granted for informed consent and HIPPA requirements.  The study 
objective is to assess patient reported efficacy of Botulinum toxin-A for the prophylaxis 
of Migraine headaches in patients with frequent Migraine headaches prior to initiation of 
treatment with Botulinum toxin-A compared to post treatment.  The research plan as 
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previously discussed is to present questions addressing the patient status prior to the 
initiation of treatment as well as post treatment.  Patient quality of life change, duration 
and frequency headache improvement are the primary focus.  Other considerations 
included the cost difference between the previous use of other treatment and the periodic 
treatment with botulinum toxin-A. Methodology is a cross sectional study utilizing a 
questionnaire consisting of a modified Migraine Disability Assessment (MIDAS) 
questions were given to patients by the principle investigator or a significant member of 
the study who has undergone the required privacy training.  Qualified patients are those 
who had received at least two series of injections. New patients who have not yet 
received treatment are excluded.  The patients are currently under treatment at both Bay 
Pines VA neurology in St Petersburg, Fl and James A Haley VA pain clinic in Tampa, Fl. 
Patients who reported chronic Migraine headaches and were refractory to previous 
treatment methods were screened and placed in programs utilizing intramuscular 
injection of Botulinum toxin-A at standard points on the face, Temporalis muscle and 
paracervical muscles.  The study’s anticipated impact and significance relate to the fact 
that patients that are debilitated by recurrent chronic migraine headaches suffer loss of 
productive time at work and home.  Treatment with Botulinum toxin-A may results in 
significant relief allowing fewer days lost at work and improved quality of life.  There 
may be significant cost saving if treatment results in discontinuation of other medications 
previously used for treatment of migraine headaches or decreased use of hospital and 
emergency department facilities.  This study utilizes a questionnaire consisting of a 
modified Migraine Disability Assessment (MIDAS) questions will be given to patients 
who had received more than one series of injections.  Included in the study are Male or 
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Female veterans age 21 – 65 currently under treatment with Botulinum toxin-A for 
migraine headache prophylaxis.  Exclusion criteria consist of patients less than 21 years 
of age, initial treatment, over 65 years of age or physician clinical judgment for 
exclusion.  Questionnaire filled out by the patient or by one of the attending physicians 
with proper privacy training with no personal health information on the form and 
voluntary participation as outlined on the cover sheet. Statistical analysis through patient 
response to a standardized questionnaire with weighted responses.  Classification is based 
on existing patients currently undergoing care at the 2 neurology clinics who have 
already been screened to qualify for the procedure by the respective departments.  The 
study is designed to extend no longer than 60 days following the start of initiating the 
questionnaire to prevent duplication of responses.  This is assured since the patient 
treatment is no more frequent than every 90 – 120 days. 
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Data Collection and Analysis 
Patients at both James A Haley VA Department of Neurology Pain Clinic and Bay Pines 
Neurology Clinic who were currently undergoing treatment for migraine headaches with 
Botulinum toxin-A were randomly presented with the survey.  The patients were 
screened per protocol to meet the criteria for the study.  Since the patients were already 
undergoing treatment with Botulinum toxin-A for persistent refractory migraine 
headaches, they were already presumed to fit the definition of chronic daily headaches.  
Due to unplanned inconsistency in offering the questionnaire to the patients, the qualified 
respondents were randomly chosen and answered the survey.  A total of 46 patients were 
surveyed at both Bay Pines VA and James A Haley VA.  19 patients were being treated at 
Bay Pines VA Neurology Clinic and 27 were under care at James A Haley VA 
Department of Neurology Pain Clinic.  Of the 46 total patients surveyed, 10 were female 
and 36 were male.  Due to IRB concerns at Bay Pines VA, the age variable was not 
recorded on surveys that were filled out in the Neurology Department there.  Gender was 
recorded at both facilities as previously noted.  The questions were graded according to 
responses to days affected by headache for 3 months prior to initiation of treatment and 
compared to responses of the same question modified to reflect the patient’s condition for 
3 months following at least one treatment.  The first question of the questionnaire relates 
to the affect of migraine headaches on the patient’s work.  The second question relates 
lost work productivity.  Question three asks about the ability of the patient to do 
housework during their migraine episodes.  Similarly question four relates to interference 
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and decreased ability to effectively do housework, but not prevent it, due to migraine 
episodes.  The fifth question asks about how the headache would interfere with family or 
social events.  The 2 following questions labeled A and B on the MIDAS questionnaire 
were designated as 6 and 7 on the study pre and post questionnaire.  They request the 
patient’s assessment of frequency of headaches in days over the previous three months 
and severity of headaches as graded on a scale of 1 – 10.  The MIDAS grading system 
contains a scale from I – IV.  For simplicity purposes and data analysis, these are 
designated as 1 – 4 when interpreting the responses on the questionnaire (Table 1).  
Responses to questions 1 – 5 are converted from number of days reported to appropriate 
MIDAS grading scores.  Since cost of treatment is a component of this study, section 8 
asks additional questions regarding use of medications for treatment of migraine 
headaches pre and post Botulinum toxin-A.  Question 9 asks the patient to assess the 
quality of life prior to and after treatment with Botulinum toxin-A.  The final question on 
the post treatment questionnaire refers to the total number of treatments that the patient 
has had.   
 42
 
Table 1 
Grade Definition Days 
Grade 1 Minimal or Infrequent Disability 0-5 
Grade 2 Mild or Infrequent Disability 6-10 
Grade 3 Moderate Disability 11-20 
Grade 4 Severe Disability 21+ 
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Results 
The mean age of the patients surveyed was confined to responses from James A Haley 
VA only due to the previously mentioned issues with Bay Pines VA IRB.   Among those 
surveyed, the mean age was 51.8 with a range from 30 to 65 years of age.  The ratio of 
males to females surveyed at both facilities was 3.6:1.  Comparisons of responses to 
questions 1- 9 were analyzed using paired T-test, with the patient’s pre-treatment status 
as the control, and Wilcoxon Signed Ranks Test.  In Table 2 we see the results of paired 
samples statistics for questions 1 – 5. In response to question 1 regarding disability 
relating to the frequency of lost work days, the mean level of disability as indicated by 
the MIDAS score is reduced overall for the 46 respondents from a score of Grade 2 to 
Grade 1 with a mean reduction of .957 (Table 4).  95% confidence interval was .626 to 
1.288 with a T-score of 5.82.  When evaluating the results by Wilcoxon Signed Ranks 
Test, the number of patients who indicated a reduction in overall disability days is equal 
to those who indicated no change (Table 13).   In analyzing the effect on interference 
with productivity at work, response to question 2 resulted in an overall mean reduction 
from Grade 3 to Grade 1.  There was a mean reduction of 1.391 with a 95% confidence 
interval of 1.051 to 1.731 and a T-score of 8.244.   Wilcoxon Signed Ranks Test revealed 
32 respondents indicated a reduction in disability with 14 respondents indicating no 
change.  In order to evaluate the effect that migraine headaches have on activities of daily 
living, question 3 asks how often the patient was prevented from performing daily 
housework.  Assessment of the responses reveals a reduction overall from Grade 3 to 
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Grade 1 with a mean reduction of 1.28 at a 95% confidence interval of   .947 to 1.618 and 
a t-score of 7.707 (Table4). Wilcoxon Signed Ranks Test analysis indicated that there 
were 31 respondents that reported a reduction in disability days and 15 that indicated no 
change (Table 13).  Overall days where productivity was diminished regarding activities 
of daily living were addressed in question 4.  The response indicated that there was an 
overall reduction from Grade 3 to Grade 1with a mean reduction of 1.457 at a 95% 
confidence interval of 1.088 to 1.825 with a t score of 7.954.  Wilcoxon Signed Ranks 
Test analysis indicated 32 respondents had a reduction in MIDAS score while 13 had no 
change and 1 patient reported an actual increase in MIDAS score.  The effect on social 
life and family activities is another area of concern which is addressed in question 5.  
According to the respondents there was a reduction in disability score from Grade 3 to 
Grade 1 with a mean reduction of 1.174 at 95% confidence interval of .829 to 1.519 with 
a T-score of 6.860.  Wilcoxon Signed Ranks Test analysis reveals 28 respondents with a 
reduction in MIDAS score and 18 with no change in social or family activities.  Question 
6 asks the patient to record how many headaches they had in the 3 months prior to 
initiation of treatment and 3 months prior to the questionnaire post botulinum toxin-A 
treatment.  Analysis of the responses demonstrates that there is a mean reduction of 
41.957 headache days with a 95% confidence interval of 32.936 to 50.977 and a T-score 
of 9.368(Table 7).  Wilcoxon Signed Ranks Test analysis reveals 42 patients reporting a 
reduction in frequency of headaches and 4 reporting no change (Table 16).  Patients were 
asked to rate the severity of their headaches in question 7 based upon a standard scale of 
0 – 10 with 0 being no pain and 10 being pain as bad as it could be.  Analysis of the 
responses shows that there is an overall reduction of pain scores from a mean of 8.85 
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prior to treatment to 5.09 post treatment (Table 5) giving a mean reduction of 3.76  at a 
95% confidence interval of  3.03 to 4.49 with a T-score of 10.368 (Table 5-7) .  Wilcoxon 
Signed Ranks Test analysis reveals 40 patients reporting a reduction in the severity of 
their headaches, 1 reporting an increase in severity and 5 indicating no change in 
headache severity (Table 16).  There is a lot of variability when evaluating medication 
usage.  The type of medication used can vary greatly in price and frequency of usage.  To 
simplify this, medications were placed on general categories.  Weekly acetaminophen 
usage, as reflected in Tables 8-10, appeared to be reduced post treatment from a mean of 
11.74 to 2.20 (Table 8) with a mean reduction of 9.04 at a 95% confidence interval 
between 1.476 to 16.611 and a T-score of 2.407 (Table 10). A breakdown of usage by 
Wilcoxon Signed Ranks Test analysis reveals 18 patients reporting a reduction, 26 
patients indicating no change and 2 patients indicating an increase in usage (Table 17).   
General use of NSAIDs also showed reduction in use post treatment from a mean of 
12.67 to 1.91 with a mean reduction of 10.761 at a 95% confidence interval between 
4.518 to 17.004 and a T-score of 3.471.  Wilcoxon Signed Ranks Test analysis indicates 
20 patients reported a decrease in use, 1 increase in usage and 25 with no change in use. 
Use of opiates showed a decrease from a mean of 7.80 to 3.39 with a mean reduction of 
4.413 at a 95% confidence interval between 1.743 to 7.083 and a T-score of 3.329.  
Wilcoxon Signed Ranks Test analysis shows 19 patients with a decrease in weekly use, 2 
with an increase and 25 with no change in weekly use.  Weekly Triptan use was reduced 
from a mean of 1.22 to .52 with a mean reduction of .696 at a 95% confidence interval of 
2.24 to 1.168 and a T-score of 2.968.  Wilcoxon Signed Ranks Test analysis reveals 14 
patients reporting a decrease, 1 reporting an increase and 31 with no change (Table 18).  
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Response to use of psychotropic medications for treatment of migraine headaches 
showed a mean reduction from 3.54 to 1.24 with a mean reduction of 2.28 at a confidence 
interval of .528 to 3.983 and a T-score of 2.704. Wilcoxon Signed Ranks Test analysis 
indicates 11 patients with an increase in weekly use and 35 with no change.  Other 
medications can consist of a wide variety including Ergotamines and Tramadol.  The 
responses from the 46 patients reveal a mean reduction in weekly use from 2.54 to 1.70 
with a mean reduction of .848 at a 95% confidence interval of -1.351 to 3.047 and a T-
score of .776. Wilcoxon Signed Ranks Test analysis shows 9 patients reporting a 
reduction, 2 with an increase in use and 35 with no change in weekly usage.  Overall 
quality of life showed an increase from a mean score of 3.20 to 7.17 (Table 11) with a 
mean improvement of 3.978 at a 95% confidence interval of -4.746 to -3.210 and a T-
score of -10.433 (Table 13).  Wilcoxon Signed Ranks Test analysis shows 1 patient 
indicating a decrease in quality of life, 41 indicating an improvement and 4 with no 
change (Table 19).  Of the 46 patients responding to the questionnaire, 40 responded to 
the final question of number of treatments.  The mean of those who responded was 10.2.  
Figures 1 – 14 graphically represent the pre and post responses of each patient to the 
questions on the survey.   
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Paired Sample Tests 
 Table 2                                     Paired Samples Statistics 
  Mean N Std. Deviation Std. Error Mean 
Pair 1 Pre1 2.20 46 1.222 .180 
Post1 1.24 46 .766 .113 
Pair 2 Pre2 2.72 46 1.167 .172 
Post2 1.33 46 .790 .117 
Pair 3 Pre3 2.67 46 1.194 .176 
Post3 1.39 46 .930 .137 
Pair 4 Pre4 2.72 46 1.223 .180 
Post4 1.26 46 .648 .095 
Pair 5 Pre5 2.46 46 1.295 .191 
Post5 1.28 46 .688 .102 
 
Table 3                                     Paired Samples Correlations 
  N Correlation Sig. 
Pair 1 Pre1 & Post1 46 .448 .002
Pair 2 Pre2 & Post2 46 .367 .012
Pair 3 Pre3 & Post3 46 .458 .001
Pair 4 Pre4 & Post4 46 .235 .115
Pair 5 Pre5 & Post5 46 .450 .002
 48
 
Table 4                                          Paired Samples Test 
 
    Paired Differences    
 95% Confidence 
Interval 
of the Difference
 
 
Mean 
Std. 
Deviation
Std. 
Error 
Mean Lower Upper t df 
Sig. 
(2-
tailed)
Pair 
1 
Pre1 - 
Post1 
.957 1.115 .164 .626 1.288
5.820 45 .000
Pair 
2 
Pre2 - 
Post2 
1.391 1.145 .169 1.051 1.731
8.244 45 .000
Pair 
3 
Pre3 - 
Post3 
1.283 1.129 .166 .947 1.618 7.707 45 .000
Pair 
4 
Pre4 - 
Post4 
1.457 1.242 .183 1.088 1.825 7.954 45 .000
Pair 
5 
Pre5 - 
Post5 
1.174 1.161 .171 .829 1.519 6.860 45 .000
 
Table 5                                      Paired Samples Statistics 
 
Mean N 
Std. 
Deviation 
Std. Error 
Mean 
Pair 1 Pre6 62.89 62.89 46 29.411 4.336
Post6 20.93 20.93 46 25.404 3.746
Pair 2 Pre7 8.85 8.85 46 1.095 .161
Post7 5.09 5.09 46 2.439 .360
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Table 6                                   Paired Samples Correlations 
 N Correlation Sig. 
Pair 1 Pre6 & 
Post6 
46 .393 .007
Pair 2 Pre7 & 
Post7 
46 .205 .172
 
Table 7                                                Paired Samples Test 
 Paired Differences  
 
 95% Confidence 
Interval of the 
Difference 
t df 
Sig. 
(2-
tailed)Mean 
Std. 
Deviation
Std. 
Error 
Mean Lower Upper 
Pair 1 Pre6 - 
Post6 
41.957 30.376 4.479 32.936 50.977 9.368 45 .000 
Pair 2 Pre7 - 
Post7 
3.761 2.460 .363 3.030 4.491 10.368 45 .000 
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Table 8                                               Paired Samples Statistics 
 
Mean N 
Std. 
Deviation 
Std. Error 
Mean 
Pair 1 Tyl Pre 11.74 46 24.848 3.664
Tyl Post 2.70 46 6.073 .895
Pair 2 NSAID Pre 12.67 46 21.170 3.121
NSAID 
Post 
1.91 46 4.273 .630
Pair 3 Opiate Pre 7.80 46 11.299 1.666
Opiate Post 3.39 46 8.131 1.199
Pair 4 Triptan Pre 1.22 46 2.021 .298
Triptan 
Post 
.52 46 .752 .111
Pair 5 PSY Pre 3.52 46 6.595 .972
Psy Post 1.24 46 3.484 .514
Pair 6 Other Pre 2.54 46 6.735 .993
Other Post 1.70 46 6.759 .997
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Table 9                     Paired Samples Correlations 
  N Correlation Sig. 
Pair 1 Tyl Pre & Tyl Post 46 .016 .914 
Pair 2 NSAID Pre & NSAID Post 46 .135 .371 
Pair 3 Opiate Pre & Opiate Post 46 .615 .000 
Pair 4 Triptan Pre & Triptan Post 46 .698 .000 
Pair 5 PSY Pre & Psy Post 46 .497 .000 
Pair 6 Other Pre & Other Post 46 .398 .006 
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Table 10                                                  Paired Samples Test 
  Paired Differences 
t df 
Sig. 
(2-
taile
d) 
 95% 
Confidence 
Interval of the 
Difference 
Mea
n 
Std. 
Devia
tion 
Std. 
Error 
Mean Lower 
Uppe
r 
Pair 
1 
Tyl Pre - Tyl 
Post 
9.04
3
25.48
3
3.757 1.476 16.61
1
2.4
07 
45 .02
0
Pair 
2 
NSAID Pre - 
NSAID Post 
10.7
61
21.02
4
3.100 4.518 17.00
4
3.4
71 
45 .00
1
Pair 
3 
Opiate Pre - 
Opiate Post 
4.41
3
8.990 1.326 1.743 7.083 3.3
29 
45 .00
2
Pair 
4 
Triptan Pre - 
Triptan Post 
.696 1.590 .234 .224 1.168 2.9
68 
45 .00
5
Pair 
5 
PSY Pre - 
Psy Post 
2.28
3
5.726 .844 .582 3.983 2.7
04 
45 .01
0
Pair 
6 
Other Pre - 
Other Post 
.848 7.406 1.092 -1.351 3.047 .77
6 
45 .44
2
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Table 11                                Paired Samples Statistics 
 Mean N Std. Deviation Std. Error Mean
 
Pair 1 
PreQual 3.20 46 1.614 .238
PostQual 7.17 46 2.069 .305
 
Table 12                 Paired Samples Correlations 
  N Correlation Sig. 
Pair 1 PreQual & PostQual 46 .030 .846
 
Table 13                                         Paired Samples Test 
 Paired Differences 
t df 
Sig. 
(2-
tailed)Mean 
Std. 
Deviation
Std. 
Error 
Mean
95% 
Confidence 
Interval of the 
Difference 
Lower Upper
Pair 
1 
PreQual 
- 
PostQual 
-
3.978 
2.586 .381 -4.746 -
3.210
-
10.433 
45 .000
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Wilcoxon Signed Ranks Test 
Table 14:                                                   Ranks 
    N Mean Rank Sum of Ranks 
Post1 – Pre1 Negative Ranks 23a 12.00 276.00
Positive Ranks 0b .00 .00
Ties 23c   
Total 46   
Post2 – Pre2 Negative Ranks 32d 16.50 528.00
Positive Ranks 0e .00 .00
Ties 14f   
Total 46   
a. Post1 < Pre1; b. Post1 > Pre1; c. Post1 = Pre1 
d. Post2 < Pre2; e. Post2 > Pre2; f. Post2 = Pre2 
Test Statisticsb 
  Post1 - Pre1 Post2 - Pre2 
Z -4.256a -5.004a
Asymp. Sig. (2-tailed) .000 .000
a. Based on positive ranks. b. Wilcoxon Signed Ranks Test 
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Table 15:                                                 Ranks 
  N Mean Rank Sum of Ranks 
Post3 - Pre3 Negative Ranks 31a 16.00 496.00
Positive Ranks 0b .00 .00
Ties 15c   
Total 46   
Post4 - Pre4 Negative Ranks 32d 17.36 555.50
Positive Ranks 1e 5.50 5.50
Ties 13f   
Total 46   
Post5 - Pre5 Negative Ranks 28g 14.50 406.00
Positive Ranks 0h .00 .00
Ties 18i   
Total 46   
a. Post3 < Pre3; b. Post3 > Pre3; c. Post3 = Pre3; d. Post4 < Pre4; e. Post4 > Pre4; f. 
Post4 = Pre4; g. Post5 < Pre5; h. Post5 > Pre5; i. Post5 = Pre5 
Test Statistics b 
 Post3 - Pre3 Post4 - Pre4 Post5 - Pre5 
Z -4.928a -4.983a -4.687a
Asymp. Sig. (2-tailed) .000 .000 .000
a. Based on positive ranks. b.  Wilcoxon Signed Ranks Test 
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Table 16:                                               Ranks 
 
N Mean Rank 
Sum of 
Ranks 
Post6 - Pre6 Negative Ranks 42a 21.50 903.00
Positive Ranks 0b .00 .00
Ties 4c   
Total 46   
Post7 - Pre7 Negative Ranks 40d 21.38 855.00
Positive Ranks 1e 6.00 6.00
Ties 5f   
Total 46   
a. Post6 < Pre6; b. Post6 > Pre6; c. Post6 = Pre6; d. Post7 < Pre7; e. Post7 > Pre7; 
f. Post7 = Pre7 
Test Statistics b 
 Post6 - Pre6 Post7 - Pre7 
Z -5.647a -5.521a
Asymp. Sig. (2-tailed) .000 .000
a. Based on positive ranks. b. Wilcoxon Signed Ranks Test 
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Table 17:                                               Ranks 
  N Mean Rank Sum of Ranks 
Tyl Post - Tyl 
Pre 
Negative Ranks 18a 10.11 182.00
Positive Ranks 2b 14.00 28.00
Ties 26c   
Total 46   
NSAID Post - 
NSAID Pre 
Negative Ranks 20d 11.50 230.00
Positive Ranks 1e 1.00 1.00
Ties 25f   
Total 46   
Opiate Post - 
Opiate Pre 
Negative Ranks 19g 11.00 209.00
Positive Ranks 2h 11.00 22.00
Ties 25i   
Total 46   
a. Tyl Post < Tyl Pre; b. Tyl Post > Tyl Pre; c. Tyl Post = Tyl Pre; d. NSAID Post < 
NSAID Pre; e. NSAID Post > NSAID Pre; f. NSAID Post = NSAID Pre; g. Opiate 
Post < Opiate Pre; h. Opiate Post > Opiate Pre; i. Opiate Post = Opiate Pre.  
Test Statistics b 
 Tyl Post - Tyl 
Pre 
NSAID Post - 
NSAID Pre 
Opiate Post - 
Opiate Pre 
Z -2.876a -3.982a -3.258a
Asymp. Sig. (2-tailed) .004 .000 .001
a. Based on positive ranks. b. Wilcoxon Signed Ranks Test 
 
 58
Table 18:                                                Ranks 
 
N 
Mean 
Rank 
Sum of 
Ranks 
Triptan Post - Triptan Pre Negative Ranks 14a 8.32 116.50
Positive Ranks 1b 3.50 3.50
Ties 31c   
Total 46   
Psy Post - PSY Pre Negative Ranks 11d 6.00 66.00
Positive Ranks 0e .00 .00
Ties 35f   
Total 46   
Other Post - Other Pre Negative Ranks 9g 5.83 52.50
Positive Ranks 2h 6.75 13.50
Ties 35i   
Total 46   
a. Triptan Post < Triptan Pre; b. Triptan Post > Triptan Pre; c. Triptan Post = Triptan 
Pre; d. Psy Post < PSY Pre; e. Psy Post > PSY Pre; f. Psy Post = PSY Pre; g. Other 
Post < Other Pre; h. Other Post > Other Pre; i. Other Post = Other Pre. 
Test Statistics b 
 Triptan Post - 
Triptan Pre 
Psy Post - 
Psy Pre 
Other Post - 
Other Pre 
Z -3.255a -3.207a -1.746a
Asymp. Sig. (2-tailed) .001 .001 .081
a. Based on positive ranks. b. Wilcoxon Signed Ranks Test 
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Table 19:                                              Ranks 
  N Mean Rank Sum of Ranks 
PostQual - 
PreQual 
Negative Ranks 1a 17.50 17.50
Positive Ranks 41b 21.60 885.50
Ties 4c   
Total 46   
a. PostQual < PreQual; b. PostQual > PreQual; c. PostQual = PreQual 
Test Statistics b 
  PostQual - PreQual 
Z -5.444a
Asymp. Sig. (2-tailed) .000
a. Based on negative ranks. b. Wilcoxon Signed Ranks Test. 
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Figure 9 
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Figure 11 
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Figure 13 
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Conclusion 
According to the patients’ response to this survey, it appears that there was an overall 
improvement in the patients’ ability to do work, for those who were employed, as well as 
their ability to do activities of daily living post treatment with Botulinum toxin-A.  From 
the patients’ response there was an approximate 67% decrease in the mean frequency of 
headaches over the surveyed pre and post 3 month periods.  The intensity of headaches 
also demonstrated a mean decrease from approximately 9/10 to 5/10 from pre to post 
treatment.  When estimating the cost of treatment, prices for each class of medication 
were calculated using an estimated average for the prescription strength of each class of 
medication.  The estimated cost of Acetaminophen 325mg is about $.17 per capsule.  
Having a mean reduction in weekly use of approximately 9 pills doesn’t really amount to 
a tremendous cost saving and over a 3 month period it would translate to approximately 
$18.36 saved.  Similarly inexpensive are NSAIDs.  At an average price using the most 
commonly prescribed/recommended NSAIDs (Ibuprofen 800mg, Naproxen 500mg, 
Nabumetone 750mg and Fiorinal 50/325/40), the average price per pill is $1.66.  There 
was a mean reduction of 10.76 pills per week according to the survey responses.  This 
translates to a weekly reduction of $17.87 and a 3 month saving of approximately 
$214.36.  Mean weekly opiate use reduction was 4.413.  At and average cost of the most 
commonly prescribed narcotic analgesics (Hydrocodone, Oxycodone, Meperidine as well 
as combination with non narcotic analgesics) of $2.41 per pill, the overall savings for the 
3 month period would be estimated at $127.62.  The most expensive medications of this 
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survey were the Triptans.  Using an average per dose price for the most commonly 
prescribed of this group (Maxalt, Imitrex and Zomig), the average price per oral dose was 
approximately $26.53.  With a mean reduction of .696 per week at a 3 month time frame, 
the estimated cost saving would be $221.58.  The use of psychotropic medications, such 
as Trazadone 100mg, Amitryptyline 50mg and Divalproex sodium 250mg, was estimated 
at an average price of $2.34 per pill.  Calculation of 3 month use was reduced by a mean 
weekly drop of 2.253 results in a saving of $63.26.  There are numerous other 
medications that are used to treat migraine headaches however for simplicity purposes I 
chose to evaluate Tramadol 50mg and Cafergot 1-100.  The average price per dose for 
these two medications is approximately $2.67.  With a mean weekly reduction of .848, 
the 3 month saving would translate to approximately $27.17.  The cost of each treatment 
with Botulinum toxin A for the VA facilities participating in this study is about $400.00.  
There was a reported mean increase in overall quality of life from 3.20 to 7.17 on the 
scale of 0 (non functional) to 10 (excellent).  When interviewing the patients the majority 
of those responding indicated overall satisfaction with their treatment.  The mean number 
of treatments was 10.2.    
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Discussion 
When interpreting the results of the respondents to this survey, a few concerns come to 
mind.  The first thought is that I was unable to evaluate responses from patients who may 
have had adverse response or stopped treatment due to lack of response.  There is also 
some technical difficulty in ensuring that the response only involves information relating 
to migraine headache and not other chronic pain conditions that may also coexist.  Also 
when evaluating pain medication usage, limiting responses only to those medications 
used for the treatment of migraine headaches proved challenging since some medications 
were used for other chronic pain conditions concurrently.  It is difficult to get an accurate 
cost analysis since there is a tendency to have multiple prescription medications and over 
the counter medications used in efforts to treat and prevent chronic migraine headaches.  
Also the cost of the medications, particularly Triptans, will vary greatly according to the 
route administered.  Another cost factor that was occasionally revealed by the 
respondents is the frequency of visits to the emergency room for treatment of migraine 
headaches.  Though it was not evaluated by this study, some of the respondents did reveal 
frequent visits to the emergency room which they indicate were reduced or eliminated 
post treatment.  Overall it appears that the use of Botulinum toxin-A in the treatment of 
migraine headaches does have some clinical value and can possibly be used in refractory 
cases to help increase the patients functional capacity and possibly reduce the cost of 
treatment by reducing multiple prescription medication use and reduce the frequency of 
visits to emergency rooms. 
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